New vaccine combo aims to shrink liver tumors in advanced cancer

NCT ID NCT05528952

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a cancer vaccine (UCPVax) to standard immunotherapy (atezolizumab and bevacizumab) can shrink tumors better than standard therapy alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior systemic treatment will participate. The main goal is to see how many patients have their tumors shrink or disappear after 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

CH William Morey
RECRUITING

Chalon-sur-Saône, France
CH de Mulhouse
RECRUITING

Mulhouse, France
CHU de Besançon
RECRUITING

Besançon, France
CHU de Montpellier
RECRUITING

Montpellier, France
CHU de Poitiers
NOT_YET_RECRUITING

Poitiers, France
Centre Georges François Leclerc
RECRUITING

Dijon, France
Centre Hospitalier Paris St Joseph
NOT_YET_RECRUITING

Paris, France
Groupe Hospitalier Paris Salpetrière
RECRUITING

Paris, France
Hôpital BEAUJON
RECRUITING

Paris, France
Hôpital Henri Mondor
RECRUITING

Créteil, France
Hôpital Nord Franche-Comté
RECRUITING

Montbéliard, France
Hôpital Paul Brousse
RECRUITING

Villejuif, France
Institut Mutualiste Montsouris
RECRUITING

Paris, France
Institut de Cancérologie de l'Ouest
NOT_YET_RECRUITING

Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.